Overall. Our data suggest that mutations in CHEK2 may contribute to prostate cancer risk and that the DNA-damage-signaling pathway may play an important role in the development prostate cancer.
... CHEK2 * 1100delC mutation ( 1.4 % ) compared with 2 % ( 21/1035 ) of unselected patients with breast cancer . Interestingly , studies that examined the prevalence of CHEK2 * 1100delC in US population controls observed a lower frequency ...
Steven R. Goodman. CHEK2. and. Cancer. The first evidence that genetic alteration in CHEK2 may predispose to cancer was the detection of rare CHEK2 germline mutations in families with a form of LFS. LFS is a familial cancer syndrome first ...
... CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 2004; 83:91–93. Oldenburg RA, Kroeze-Jansema K, Kraan J, et al. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case ...
... CHEK2 gene is not present in Spanish familial breast cancer population . Int J Cancer 108 , 54–56 . 139. Rajkumar , T. , Soumittra , N. , Nancy , N.K. , Swaminathan , R. , Sridevi , V. , and Shanta , V. ( 2003 ) . BRCA1 , BRCA2 and CHEK2 ...
... (CHEK2) is a DNA damage-activated protein kinase implicated in cell cycle checkpoint control. The significance of CHEK2 alterations for breast cancer incidence and clinical behavior is not clear.” Our news editors obtained a quote from ...
... CHEK2 gen encodes cell cycle checkpoint kinase 2 that participates in the DNA repair pathway, cell cycle regulation and apoptosis. Mutations in CHEK2 gene may result in kinase inactivation or reduce both catalytic activity and ...